Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Fri, 7 Feb 01:30 pm

Indian share markets pared early gains but continued to trade higher in the post-noon trading session. Majority of the sectoral indices are trading in the green with metal, pharma and realty witnessing maximum buying interest. Only FMCG, IT and consumer durable stocks are trading in the red.

BSE-Sensex is up 40 points and NSE-Nifty is trading 14 points up. BSE Mid Cap is trading 0.6% up and BSE Small Cap index is trading up by 0.5%. The rupee is trading at 62.2 to the US dollar.

Majority of the automobile stocks are trading in the green with Bajaj Auto and Escorts being among major gainers whereas TVS Motors and Eicher Motors are the biggest losers. As per a leading financial daily, Tata Motors is aiming to achieve 15% growth in revenues from the defence business over the next two years. The company is trying to expand its defence business in ASEAN countries such as Thailand, Malaysia and Indonesia. The company recently signed a distributorship agreement for defence vehicles for Indonesia. Tata Motors has been in association with India's off-road defence and security forces since 1958. Tata Motors stock is presently trading up 0.8%.

Most of the Indian pharma stocks are trading firm with Aurobindo Pharma and Biocon leading the pack of gainers while Panacea Biotech and Ranbaxy Labs are a few stocks trading in the red. As per a leading business daily, the Indian arm of the Swiss pharma company Roche has sued Biocon and US generic company Mylan for launching the world's first biosimilar version of the breast cancer drug Herceptin (Trastuzumab). The company has also sued the Drug Controller General of India for giving approval for the launch of the drug. Roche had relinquished its patent on Herceptin in India last year. The Delhi High Court has issued a restraint order on Mylan and Biocon against relying or referring to Herceptin or any other data for selling or promoting their brands Canmab (Biocon) and Hertaz (Mylan) till the next hearing. According to Roche, both Biocon and Mylan have not followed the due process as per guidelines on getting approvals for biologics in India. Biocon stock is trading up 3.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.